Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy [Et randomiseret, dobbeltblindt, placebokontrolleret, verdensomspaendende, dosisbestemmende klinisk multicenterforsog i fase II med parallelle grupper med en bevis-for-effekt ledende kohorte, der vurderer sikkerhed, tolerance og effekt af MK-8457 + MTX til patienter med aktiv kronisk leddegigt pa trods af behandling med methotrexate].

X
Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy [Et randomiseret, dobbeltblindt, placebokontrolleret, verdensomspaendende, dosisbestemmende klinisk multicenterforsog i fase II med parallelle grupper med en bevis-for-effekt ledende kohorte, der vurderer sikkerhed, tolerance og effekt af MK-8457 + MTX til patienter med aktiv kronisk leddegigt pa trods af behandling med methotrexate].

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 8457 (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms AM2
  • Sponsors Merck Sharp & Dohme Corp.
  • Most Recent Events

    • 16 Aug 2016 This trial was completed in Germany (End Date:2 Sep 2013).
    • 26 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
    • 06 Dec 2012 Planned End Date changed from 1 Nov 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top